Moderna’s shares dropped 5.7% Friday morning after an initial 25% fall on Thursday, following a leak of partial data regarding its cancer vaccine developed with Merck. Despite the full data release showing promising results that beat Wall Street expectations, both companies' stocks declined amid the initial uncertainty. The setback highlights volatility in the biotech sector surrounding clinical trial data releases.

Deckers experienced a 6.7% decline after reporting fiscal second quarter earnings that missed analyst forecasts. The company posted $1.43 billion in revenue for the quarter ending Sept. 30, short of the anticipated $1.51 billion, with key brands such as HOKA and UGG underperforming expectations. This earnings miss has weighed on investor sentiment for the shoemaker’s stock.

Telecommunications stocks saw mixed moves following a Bloomberg report that SpaceX is negotiating to lease 80,000 cell towers to build a fourth nationwide wireless network. AT&T shares fell 4.2%, T-Mobile dropped 4.3%, and Verizon declined 3.6%, while tower operators Crown Castle and American Tower surged 7.6% and 5.5%, respectively. The potential SpaceX deal reflects a significant shift in the telecom landscape and investor speculation about competitive pressures.

SpaceX’s stock also received a boost from an upgrade by PhillipCapital, which raised the rating to buy from sell and lifted the price target to $250 from $75, citing strong gains in its AI segment. Meanwhile, Bloom Energy saw shares decrease 2.5% despite beating Q3 earnings and raising its full-year EPS guidance, as concerns over its negative free cash flow tempered enthusiasm. Other companies like Comfort Systems and Western Digital posted mixed results, reflecting varied market reactions to earnings reports and future outlooks.